课题基金 / 基金详情

Computationally Designed Heparan Sulfates and Pathophysiology

Computationally Designed Heparan Sulfates and Pathophysiology
计算设计的硫酸乙酰肝素和病理生理学
批准号:
9068302
负责人:
Umesh Ramanlal Desai
金额:
$44.75万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

Umesh Ramanlal Desai的其他基金

相似基金

相关文献

中文摘要
翻译
天然生物聚合物肝素和硫酸乙酰肝素在许多生物 包括凝血、生长和形态、血管生成、免疫反应、炎症、 和病原体入侵。事实上,肝素及其衍生物,低分子肝素和磺达肝素, 在临床上被用作许多血栓性疾病的抗凝剂。使用的基本依据 肝素在这些疾病中的作用是它与抗凝血酶(一种血浆)的高亲和力和高特异性相互作用。 糖蛋白和凝血酶抑制物,特别是凝血酶、凝血因子Xa和凝血因子IXa。尽管 尽管长期使用肝素,但它仍存在许多问题。更好的肝素基础 抗凝治疗是迫切需要的,特别是在它的异质性也可以给 引发与污染相关的问题。此外,尽管肝素和硫酸肝素发挥了作用 虽然在其他生理和病理过程中起着重要作用,但目前还没有临床药物被设计出来。 造成这种状况的主要原因是H/HS的结构多样性,这导致了a) 制备具有明确结构组成的HS制剂的困难以及b)研究 大量HS结构与多种蛋白质的相互作用。在这些方面有必要取得重大进展 用于解码H/HS结构-功能关系的两个区域,以便能够设计激动剂和/或 用于调节生物过程的拮抗剂。 这个项目11解决了研究所有可能的相互作用的根本困难 通过实验室开发的独特技术与任何蛋白质(即上述b区)进行HS测序 该技术称为组合虚拟文库筛选(CVLS)技术。结合项目一、三 和IV,我们建议1)破译系统结构-功能关系的基本方面 凝血和炎症系统,以及2)为了在活体动物模型中测试这种增强的理解, 尤其是对于凝血系统。因此,我们建议1)研究具体的和非具体的 用计算方法研究硫酸乙酰肝素与蛋白质的特异性相互作用 用于体外和体内研究的结构;2)开发计算机设计的HS结构作为特定的 肝素辅因子II激活剂;3)研究设计的H/HS与凝血蛋白的相互作用 在分子水平上开发为临床上有用的新抗凝剂。 相关性(请参阅说明): 在美国,三分之一的人患有血栓性疾病。拟议的研究涉及到计算 作为血栓性疾病调节剂的硫酸乙酰肝素的设计、生化评价和动物试验。
英文摘要
Natural biopolymers heparin and heparan sulfate play critical roles in a large number of biological processes including coagulation, growth and morphology, angiogenesis, immune response, inflammation, and pathogen invasion. In fact, heparin and its derivatives, low molecular weight heparins and fondaparinux, are clinically used as anticoagulants in a number of thrombotic disorders. The fundamental basis for the use of heparin in these disorders is its high affinity and high specificity interaction with antlthrombin, a plasma glycoprotein and inhibitor of coagulation enzymes, especially thrombin, factor Xa and factor IXa. Despite the longstanding use of heparin, it continues to suffer from a number of problems. Better heparin-based anticoagulation therapy is critically needed, especially at a time when its heterogeneous nature can also give rise to problems associated with contaminations. Additionally, although heparin and heparan sulfate play important roles in other physiological and pathological processes, no clinical agent has as yet been devised. The major reason for this state is the phenomenal structural diversity of H/HS, which results in a) the difficulty of preparing HS preparations with defined structural composition and b) the difficulty of studying the interaction of a large number of HS structures with multiple proteins. Major advances are necessary in these two areas to decode H/HS structure - function relationships so as to enable the design of agonists and/or antagonists for modulation of biological processes. This Project 11 of the PEG addresses the fundamental difficulty of studying the interactions of all possible HS sequences with any protein (i.e., area b) above) through a unique technology developed in the laboratory of the PL called combinatorial virtual library screening (CVLS) technology. In combination with Projects I, III and IV, we propose 1) to decipher fundamental aspects of HS structure - function relationships in the coagulation and inflammation system, and 2) to test this enhanced understanding in in vivo animal models, especially for the coagulation system. Thus, we propose to 1) study the importance of specific and non- specific interactions of heparan sulfate with proteins using computational approaches and identify promising structures for in vitro and in vivo investigation; 2) develop computationally designed HS structures as specific activators of heparin cofactor II; and 3) investigate the interaction of designed H/HS with coagulation proteins at a molecular level for development as new clinically useful anticoagulants. RELEVANCE (See instructions): Thrombotic disorders affect 1 in 3 individuals in the US. The proposed research involves the computational design, biochemical evaluation and animal testing of heparan sulfates as modulators of thrombotic disorders.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Lead identification and pre-clinical studies on allosteric inhibitors of coagulation factor XIa
  • 批准号:
    10722847
  • 项目类别:
  • 资助金额:
    $54.34万
  • 财政年份:
    2022
  • 负责人:
    Umesh Ramanlal Desai
  • 依托单位:
Lead identification and pre-clinical studies on allosteric inhibitors of coagulation factor XIa
  • 批准号:
    10369394
  • 项目类别:
  • 资助金额:
    $54.34万
  • 财政年份:
    2022
  • 负责人:
    Umesh Ramanlal Desai
  • 依托单位:
Project 3: Role of Glycosaminoglycans in Hematopoiesis
  • 批准号:
    10545019
  • 项目类别:
  • 资助金额:
    $58.96万
  • 财政年份:
    2021
  • 负责人:
    Umesh Ramanlal Desai
  • 依托单位:
Project 3: Role of Glycosaminoglycans in Hematopoiesis
  • 批准号:
    10088970
  • 项目类别:
  • 资助金额:
    $59.97万
  • 财政年份:
    2021
  • 负责人:
    Umesh Ramanlal Desai
  • 依托单位:
海外基金